Colossal bets de-extinction is the demo, gene tools are the business; $10.2B and rising

Colossal Biosciences, founded in 2021 by Dallas entrepreneur Ben Lamm, picked the most attention-dense product category on Earth: bringing extinct species back. The woolly mammoth was the flagship, with the dodo and Tasmanian tiger following, and later the dire wolf. The method was deliberately prosaic — sequence the extinct genome, compare it to the closest living relative, edit living cells with CRISPR, implant the embryo in a surrogate — but the packaging was pure spectacle, and every milestone became a headline.

The company was explicit that resurrection is the demo, not the business. Lamm told TechCrunch in January 2025, when a $200M Series C from TWG Global valued Colossal at $10.2B despite zero revenue, that investors were 'very impressed with the speed at which we've created new technologies.' The real asset, he argued, is the stack the work forces them to build: gene-editing pipelines, computational biology, surrogate reproduction — plus spinouts like Form Bio, Breaking (plastics) and Astromech (AI predictive modeling, valued at $2B by March 2026).

Milestones landed on schedule and went viral: CRISPR-edited 'woolly mice' born healthy in March 2025; dire wolf pups Remus, Romulus and Khaleesi in April 2025 — gray wolves edited with 20 appearance genes, implanted into a large domestic dog. Scientists publicly pushed back ('not de-extinction'), which Colossal absorbed as free attention while continuing to pair projects with conservation work, George R.R. Martin as adviser, and a growing roster of species (six by April 2026).

By July 2026 the startup was reportedly in talks to raise at a $20B-$30B valuation (Axios), had begun generating revenue, and had taken a $60M investment from the UAE — the clearest sign yet that the strategy was working: the mammoth buys the headlines; the tools buy the revenue.